PENNSAID®

(diclofenac sodium topical solution) 1.5% w/w

NOW AVAILABLE

Introducing the next-generation topical NSAID that treats the signs and symptoms of OA of the knee(s); the only FDA approved topical NSAID with DMSO, a proven penetrating agent.

PENNSAID 150 mL Bottle
NDC (11 digit) 23635-0310-15

Wholesaler	Ordering Number
ABC (6 digits)	**033-969**
McKesson	**1926500**
Cardinal	**4288569**



INDICATION

PENNSAID is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s).

WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK

Cardiovascular Risk

- **Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.**
- **PENNSAID is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.**

Gastrointestinal Risk

- **NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.**

IMPORTANT RISK INFORMATION

PENNSAID is also contraindicated in patients:

- With a known hypersensitivity to diclofenac sodium or any other component of PENNSAID.
- Who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.
- The most common treatment-related adverse events with PENNSAID were application site skin including dry skin (32%), contact dermatitis characterized by skin erythema and induration (9%), contact dermatitis with vesicles (2%) and pruritus (4%).
- Elevation of one or more liver tests may occur during therapy with NSAIDs. Discontinue PENNSAID immediately if abnormal liver tests persist or worsen.

Please see attached Prescribing Information, including additional Important Risk Information.

Mallinckrodt

COVIDIEN